Back to News
Market Impact: 0.2
aTyr Pharma, Inc. Files Prospectus Supplement for Up to $79,994,251 Common Stock Offering
Source: Nasdaq
Company Fundamentals
On November 6, 2026, aTyr Pharma filed an SEC prospectus supplement concerning a potential sale of its common stock, with a par value of $0.001 per share. The excerpt does not specify the amount of stock or proceeds, so the scale and potential dilution cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
Ticker Sentiment
ATYR-0.15
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO